Trial Profile

A multicenter study of RVL-001 in Rett syndrome patients

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 02 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vorinostat (Primary) ; Donepezil; Ketamine
Indications Rett syndrome
Focus Adverse reactions

Most Recent Events

02 Jun 2024 New trial record
14 May 2024 According to an Unravel Biosciences media release, announced a collaboration with Vanderbilt University Medical Center (VUMC) to provide support for VUMC's upcoming multisite clinical trial to evaluate three repurposed drugs, including an oral liquid formulation of vorinostat (Unravel's RVL-001), for the treatment of patients with Rett Syndrome.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com